Alessia Tammaro

Dr. Alessia Tammaro


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2023 in Cells
Verified
Journal Article
Open access
PDF file
RTRoberta Tassinari
Roberta Tassinari
ATAlessia Tammaro
Alessia Tammaro
GLGabriele Lori
Gabriele Lori
STSabrina Tait
Sabrina Tait
AMAndrea Martinelli
Andrea Martinelli
Francesca MaranghiFrancesca Maranghi
Francesca Maranghi
Transgender (TG) describes individuals whose gender identity differs from the social norms. TG people undergoing gender-affirming hormone therapy (HT) may be considered a sub-group of the population susceptible to environmental contaminants for their targets and modes of action. The aim of this study is to set appropriate HT doses and identify specific biomarkers to implement TG animal models. Four adult rats/group/sex were subcutaneously exposed to three doses of HT (plus control) selected starting from available data. The demasculinizing-feminizing models (dMF) were β-estradiol plus cyproterone acetate, at 0.09 + 0.33, 0.09 + 0.93 and 0.18 + 0.33 mg, respectively, five times/week. The defeminizing-masculinizing models (dFM) were testosterone (T) at 0.45, 0.95 and 2.05 mg, two times/week. Clitoral gain and sperm count, histopathological analysis of reproductive organs and liver, hormone serum levels and gene expression of sex-dimorphic CYP450 were evaluated. In the dMF model, the selected doses—leading to T serum levels at the range of the corresponding cisgender—induced strong general toxicity and cannot be used in long-term studies. In the dFM model, 0.45 mg of T represents the correct dose. In addition, the endpoints selected are considered suitable and reliable to implement the animal model. The sex-specific CYP expression is a suitable biomarker to set proper (de)masculinizing/(de)feminizing HT and to implement TG animal models.

13 September 2023 in Toxics
Verified
Journal Article
Open access
PDF file
RTRoberta Tassinari
Roberta Tassinari
ATAlessia Tammaro
Alessia Tammaro
AMAndrea Martinelli
Andrea Martinelli
MVMauro Valeri
Mauro Valeri
Francesca MaranghiFrancesca Maranghi
Francesca Maranghi
Titanium dioxide (TiO2) nanomaterial is used in several items (implant materials, pills composition, cosmetics, etc.). Although TiO2 is no longer considered safe as a food additive, the general population is exposed daily through different routes, and information is lacking on some aspects of animal and human health. This study evaluated liver and kidney toxicity of food-grade TiO2 nanoparticles (NPs) (primary size < 25 nm) in male and female rats that were orally exposed for 5 days to 0, 1, and 2 mg/kg body weight per day (comparable with daily E171 consumption). Selected liver and kidney toxicity endpoints included serum biomarkers, histopathological analysis and expression of osteopontin (SPP1), vascular endothelial growth factor (VEGF), interleukin 6 (IL-6), and neuropeptide Y (NPY). Although TiO2 NPs are known to affect the gastric mucosa, short-term exposure induced sex-specific effects: general toxicity parameters were predominantly altered in female rats, whereas the liver appeared to be more affected than the kidneys in male rats, which also showed overexpression of NPY and SPP1. In the kidneys, the TiO2 NP effects were quantitatively similar but qualitatively different in the two sexes. In conclusion, careful consideration should be paid to the presence of TiO2 NPs in other items that can lead to human exposure.

10 January 2025 in Journal of Visualized Experiments
Verified
Journal Article
Closed access
PDF file
GLGabriele Lori
Gabriele Lori
ATAlessia Tammaro
Alessia Tammaro
AMAndrea Martinelli
Andrea Martinelli
LCLuigia Cancemi
Luigia Cancemi
PFPaolo Frassanito
Paolo Frassanito
Francesca MaranghiFrancesca Maranghi
Francesca Maranghi
Transgender (TG) people are individuals whose gender identity and sex assigned at birth do not match. They often undergo gender-affirming hormone therapy (GAHT), a medical intervention that allows the acquisition of secondary sex characteristics more aligned with their individual gender identity, providing consistent results in the improvement of numerous socio-psychological variables. However, GAHT targets different body systems, and some side effects are recorded, although not yet fully identified and characterized. Therefore, TG people undergoing GAHT may be considered as a susceptible sub-group of population and specific attention should be paid in the frame of risk assessment, e.g., through the use of targeted animal models. The present work describes the procedures set to implement two rat models mimicking GAHT: the demasculinizing-feminizing model (dMF) mimicking the GAHT for TG women and the defeminizing-masculinizing model (dFM) mimicking the GAHT for TG men. The models have been implemented through the administration of the same hormones used for human GAHT, namely, β-estradiol plus cyproterone acetate for dMF and testosterone for dFM, by the same routes of exposure for a 2 week period. Rats are checked daily during the treatment to evaluate health status and potentially aggressive behaviors. At sacrifice, blood and target tissues have been sampled and stored for biochemical, molecular, and histopathological analysis. Sex-specific parameters, namely, sperm count and clitoral dimensions, have also been evaluated. In addition, CYP450 isoforms, exclusively and/or preferentially expressed in male and female rat liver, are identified and characterized as novel biomarkers to verify the success of GAHT and to set the model. Thyroid involvement has also been explored as a key target in the endocrine system.

11 January 2025
Verified
Dataset
Closed access
PDF file
GLGabriele Lori
Gabriele Lori
ATAlessia Tammaro
Alessia Tammaro
AMAndrea Martinelli
Andrea Martinelli
LCLuigia Cancemi
Luigia Cancemi
PFPaolo Frassanito
Paolo Frassanito
Francesca MaranghiFrancesca Maranghi
Francesca Maranghi
Transgender (TG) people are individuals whose gender identity and sex assigned at birth do not match. They often undergo gender-affirming hormone therapy (GAHT), a medical intervention that allows the acquisition of secondary sex characteristics more aligned with their individual gender identity, providing consistent results in the improvement of numerous socio-psychological variables. However, GAHT targets different body systems, and some side effects are recorded, although not yet fully identified and characterized. Therefore, TG people undergoing GAHT may be considered as a susceptible sub-group of population and specific attention should be paid in the frame of risk assessment, e.g., through the use of targeted animal models. The present work describes the procedures set to implement two rat models mimicking GAHT: the demasculinizing-feminizing model (dMF) mimicking the GAHT for TG women and the defeminizing-masculinizing model (dFM) mimicking the GAHT for TG men. The models have been implemented through the administration of the same hormones used for human GAHT, namely, β-estradiol plus cyproterone acetate for dMF and testosterone for dFM, by the same routes of exposure for a 2 week period. Rats are checked daily during the treatment to evaluate health status and potentially aggressive behaviors. At sacrifice, blood and target tissues have been sampled and stored for biochemical, molecular, and histopathological analysis. Sex-specific parameters, namely, sperm count and clitoral dimensions, have also been evaluated. In addition, CYP450 isoforms, exclusively and/or preferentially expressed in male and female rat liver, are identified and characterized as novel biomarkers to verify the success of GAHT and to set the model. Thyroid involvement has also been explored as a key target in the endocrine system.

18 November 2022 in Preprints.org
Verified
Preprint
Open access
PDF file
RTRoberta Tassinari
Roberta Tassinari
ATAlessia Tammaro
Alessia Tammaro
GLGabriele Lori
Gabriele Lori
STSabrina Tait
Sabrina Tait
AMAndrea Martinelli
Andrea Martinelli
Francesca MaranghiFrancesca Maranghi
Francesca Maranghi
Transgender (TG) describes individuals whose gender identity differs from the social norms. Some TG people undergo gender-affirming hormone therapy (HT) and may be considered as a sub-group of population susceptible to environmental contaminants for their targets and modes of action. Aim of the work is to set appropriate HT doses and identify specific biomarkers to implement TG animal models. Four adult rats/group/sex are subcutaneously exposed to 3 doses of HT (plus control) selected starting from available data. Demasculinizing-feminizing model (dMF): β-estradiol plus cyproterone acetate: 0.09+0.33, 0.09+0.93 and 0.18+0.33 mg, 5 times/week. Defeminizing-masculinizing model (dFM): testosterone 0.45, 0.95 and 2.05 mg, 2 times/week. Clitoral gain and sperm count, histophatological analysis of reproductive organs and liver, hormone serum levels and gene expression of sex-dimorphic CYP450 are evaluated. In dMF model, the selected doses, leading to T serum levels at the range of the corresponding cisgender, induced strong general toxicity and cannot be used in long-term studies. In dFM model, 0.45 mg of testosterone represents the correct dose. In addition, the endpoints selected are considered suitable and reliable to implement the animal model. The sex-specific CYP expression is a suita-ble biomarker to set proper (de)masculinizing/(de)feminizing HT and to implement TG animal models.

13 October 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
MDMassimo D'Archivio
Massimo D'Archivio
GZGiulia Zanchi
Giulia Zanchi
ATAlessia Tammaro
Alessia Tammaro
RMRoberta Masella
Roberta Masella
CCClaudia Cataldo
Claudia Cataldo
Growing evidence suggests that the increase in global temperatures is partly driving the rise in type 2 diabetes (T2DM), with dietary choices playing a key mediating role. This review offers a novel perspective on the complex feedback loop involving gen-dered dietary behaviours, greenhouse gas emissions (GHGE), climate change, and T2DM risk. Diets high in red meat and ultra-processed foods contribute substantially to green-house gas emissions (GHGE), while plant-based diets offer both environmental and health benefits. Biological sex and gender influence physiological vulnerability and di-etary patterns, noting that women typically consume less meat and have metabolic characteristic that differently influence diabetes risk compared to men. We performed a comprehensive literature search to collect information on dietary behaviours, GHGE, ambient temperature, and diabetes outcomes, with a particular focus on sex and gen-der differences. Evidence indicates that rising global temperatures impairs glucose homeostasis, spe-cifically through a reduced activity of brown adipose tissue and increased insulin re-sistance, thereby exacerbating diabetes risk. Gender-specific dietary choices not only affect individual and collective contributions to climate change but also modulate vulnerability to climate-related health risks, including diabetes. Modelling studies suggest that shifting to plant-based diets, especially among men, could significantly reduce both GHGE and diabetes burden. These findings highlight the importance of incorporating sex and gender perspectives into dietary strategies to develop targeted mitigation measures against climate change while improving metabolic health world-wide.